New England Journal of Medicine publishes two trials for Symbicort as an anti-inflammatory reliever therapy ‘as needed’ in mild asthma

AstraZeneca today announced results from the Phase III SYGMA (https://cms.psav.com/cPaper2014/viewing/view.php?access_hash=c6af0bc86a2...) trials1 (https://www.nejm.org/doi/full/10.1056/NEJMoa1715275),2 (https://www.nejm.org/doi/full/10.1056/NEJMoa1715274) of Symbicort Turbuhaler (budesonide/formoterol) given as an anti-inflammatory reliever ‘as needed’ versus two different treatment regimens in patients with mild asthma. The data are published in the New England Journal of Medicine1,2 and will be presented on Sunday 20